HIV infection is associated with a progressive decline in immune function as evidenced by a progressive decline in the number and the repertoire of the CD4 T lymphocyte pool of the immune system. A major focus of this project is attempting to reverse this process through the use of interleukin-2 to increase the number of CD4 T lymphocytes in the setting of HIV infection. Over the past year, four phase II trials have been completed. Each of these has demonstrated that IL-2 is capable of inducing a substantial increase in CD4+ T cell count without major changes in levels of HIV. In addition, a pooled analysis of the first 157 patients enrolled in randomized, controlled trials of IL-2 have demonstrated long term substantial increases in CD4+ T cell counts, small decreases in levels of HIV and a trend towards fewer AIDS-defining illnesses. The potential of the T cell limb of the immune system to respond to different antigens is defined through the diversity of the T cell repertoire. HIV infection leads not only to a decrease in the total number of CD4 T lymphocytes, but also to a decline in the diversity of the T cell repertoire. In an attempt to expand the ability of the T cell repertoire to recognize and respond to HIV infected cells, the tools of gene therapy were utilized to create chimeric human T cells that express not only their native receptor but also a second receptor with specificity for HIV. The feasibility of this approach for the treatment of patients with HIV infection was established in a clinical trial utilizing syngeneic twin pairs discordant for HIV infection, in which cells from the healthy twin were removed, genetically modified to include a second receptor with specificity for the coat protein of HIV and then infused to the HIV-infected twin. While there did not appear to be any clinical benefit to this approach it did demonstrate that such cells could survive in vivo and that their survival was enhanced when both CD4 and CD8 T cells were transferred as opposed to the transfer of CD8 T cells alone.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000636-09
Application #
6434814
Study Section
(OCR)
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Porter, Brian O; Anthony, Kara B; Shen, Jean et al. (2009) Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial. AIDS 23:203-12
Neaton, James D; Lane, H Clifford (2008) Getting personal about treating HIV. Nat Med 14:369-70
Youle, Mike; Emery, Sean; Fisher, Martin et al. (2006) A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK-Vanguard Study. PLoS Clin Trials 1:e3
Keh, Chris E; Shen, Jean M; Hahn, Barbara et al. (2006) Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients. AIDS 20:361-9
Morgan, Richard A; Walker, Robert; Carter, Charles S et al. (2005) Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Ther 16:1065-74
Kovacs, Joseph A; Lempicki, Richard A; Sidorov, Igor A et al. (2005) Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest 115:2139-48
Lane, H Clifford; Folkers, Gregory K; Fauci, Anthony S (2005) Reports on nevirapine threaten public health. Nat Med 11:245
Farel, Claire E; Chaitt, Doreen G; Hahn, Barbara K et al. (2004) Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood 103:3282-6
Arduino, Roberto C; Nannini, Esteban C; Rodriguez-Barradas, Maria et al. (2004) CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies. Clin Infect Dis 39:115-22
de Boer, Alberdina W; Markowitz, Norman; Lane, H Clifford et al. (2003) A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 Clin Immunol 106:188-96

Showing the most recent 10 out of 26 publications